BioPharmSignal logoBioPharmSignal

Biotech News

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept (CORT)ir.corcept.com2026-05-29 20:37 ESTCommercial

REDWOOD CITY, Calif. --(BUSINESS WIRE)--May 29, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Corcept

Corcept is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

CORTCorcept2026-05-27 08:09:08 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-05-06 11:28:15 EST

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

CORTCorcept2026-05-06 11:28:15 EST

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

CORTCorcept2026-05-06 11:28:14 EST

(Español) FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Stock data

Close
69.49 USD
Market cap
7.46B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States